Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium.

Abstract:

:The influence of serum on the production of retroviral vectors by the HT1080 human fibrosarcoma-derived packaging cell line FLYRD18 was investigated. A fourfold increase in virus titer was observed under serum-free conditions, as compared with medium supplemented with 10% fetal calf serum. A similar improvement was also seen for bulk transduction efficiency. Serum had a negative and dose-dependent effect on titer without affecting cell growth, virus stability, or infectivity. In contrast to virus from NIH 3T3-derived packaging cells [Hanenberg, H., et al. (1996). Nature Med. 2, 876-882], the FLYRD18-derived virus did not adhere to fibronectin or serum proteins adsorbed at the surface of culture flasks. Electron microscopy supports the conclusion that the effect of serum is at the level of virus production by the cells. Addition of soybean trypsin inhibitor had an inhibitory effect on virus production, while pretreatment of serum with trypsin was found to enhance the retroviral titer. These results suggest that protease inhibitors present in serum may be responsible for the inhibition of virus production. The exact mechanism remains, however, to be determined. As compared with medium supplemented with 10% serum, the combination of increased virus titer and absence of exogenous protein under serum-free conditions resulted in a 300-fold increase in the virus:total protein ratio in the supernatants harvested from the FLYRD18 packaging line. This improvement enhances prospects for further concentration and purification of the virus.

journal_name

Hum Gene Ther

journal_title

Human gene therapy

authors

Gerin PA,Gilligan MG,Searle PF,Al-Rubeai M

doi

10.1089/10430349950017329

keywords:

subject

Has Abstract

pub_date

1999-08-10 00:00:00

pages

1965-74

issue

12

eissn

1043-0342

issn

1557-7422

journal_volume

10

pub_type

杂志文章
  • Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors.

    abstract::Foamy virus (FV) vectors are a promising gene delivery system for use in hematopoietic stem cell gene therapy. Previous FV vector marking studies in the NOD/SCID xenotransplantation model used umbilical cord blood (UCB)-derived SCID repopulating cells (SRCs) that were assayed 5-10 weeks posttransplantation. We now rep...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340460732481

    authors: Josephson NC,Trobridge G,Russell DW

    更新日期:2004-01-01 00:00:00

  • Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.

    abstract::The management of disorders of the nervous system remains a medical challenge. The key goals are to understand disease mechanisms, to validate therapeutic targets, and to develop new therapeutic strategies. Viral vector-mediated gene transfer can meet these goals and vectors based on lentiviruses have particularly use...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2006.17.1

    authors: Wong LF,Goodhead L,Prat C,Mitrophanous KA,Kingsman SM,Mazarakis ND

    更新日期:2006-01-01 00:00:00

  • Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease.

    abstract::The objective of this phase II investigation is to assess the safety and efficacy of a plasmid mediated approach to induce angiogenesis/arteriogenesis with the angiomatrix protein Del-1 (developmentally regulated endothelial locus 1), in subjects with intermittent claudication (IC) secondary to peripheral arterial dis...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1089/104303404323142060

    authors: Rajagopalan S,Olin JW,Young S,Erikson M,Grossman PM,Mendelsohn FO,Regensteiner JG,Hiatt WR,Annex BH

    更新日期:2004-06-01 00:00:00

  • Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium.

    abstract::Defined serum-free conditions have great conceptual advantages for the biological safety and standardization of clinical gene transfer into hematopoietic stem cells. In the only study reported to date, Sekhar et al. achieved low serum conditions by a complex concentration procedure of a retroviral supernatant initiall...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.6-771

    authors: Glimm H,Flügge K,Möbest D,Hofmann VM,Postmus J,Henschler R,Lange W,Finke J,Kiem HP,Schulz G,Rosenthal F,Mertelsmann R,von Kalle C

    更新日期:1998-04-10 00:00:00

  • Development of adoptive cell therapy for cancer: a clinical perspective.

    abstract::Adoptive cellular therapy provides the promise of a potentially powerful general treatment for cancer. Although this is a complex and challenging field, there have been major advances in basic and translational research resulting in clinical trial activity that is now beginning to confirm this promise. However, these ...

    journal_title:Human gene therapy

    pub_type: 杂志文章,评审

    doi:10.1089/hum.2010.086

    authors: Hawkins RE,Gilham DE,Debets R,Eshhar Z,Taylor N,Abken H,Schumacher TN,ATTACK Consortium

    更新日期:2010-06-01 00:00:00

  • hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial.

    abstract::Eleven patients with moderate to severe erectile dysfunction (ED) were given a single-dose corpus cavernosum injection of hMaxi-K, a "naked" DNA plasmid carrying the human cDNA encoding hSlo (for human slow-poke), the gene for the alpha, or pore-forming, subunit of the human smooth muscle Maxi-K channel. Three patient...

    journal_title:Human gene therapy

    pub_type: 杂志文章,多中心研究

    doi:10.1089/hum.2006.17.1165

    authors: Melman A,Bar-Chama N,McCullough A,Davies K,Christ G

    更新日期:2006-12-01 00:00:00

  • Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response.

    abstract::Gene therapy for heart diseases requires availability of an efficient vector for gene transfer into myocardium. Recombinant adenovirus expressing the Escherichia coli beta-galactosidase (beta-Gal) gene was shown to infect rat cardiocytes efficiently in vivo. However, a time course of gene expression showed that transg...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.10-1265

    authors: Gilgenkrantz H,Duboc D,Juillard V,Couton D,Pavirani A,Guillet JG,Briand P,Kahn A

    更新日期:1995-10-01 00:00:00

  • Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection.

    abstract::Gutted adenoviral (Ad) vectors have a greater cloning capacity and elicit less immune response than conventional Ad vectors. Unfortunately, clinical use of gutted vectors has been slowed by production difficulties, including low yield and a tendency for recombinant virus to emerge. These two problems are related, beca...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340252809810

    authors: Hartigan-O'Connor D,Barjot C,Crawford R,Chamberlain JS

    更新日期:2002-03-01 00:00:00

  • A retroviral vector that allows efficient co-expression of two genes and the versatility of alternate selection markers.

    abstract::pZIG(hGCSFR) is a retroviral vector that can co-express two genes and also provides alternative selection markers. This retroviral vector has been constructed to incorporate an internal ribosome entry site (IRES) element to co-express two exogenous genes in mammalian cells. Two marker/selection genes have been cloned ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.8-979

    authors: Saleh M

    更新日期:1997-05-20 00:00:00

  • Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial.

    abstract::Immunotherapy with whole cell cancer vaccines has been tested in various tumor types. This study investigated the safety profile and antitumor activity of an allogeneic prostate carcinoma cell line, LNCaP, expressing recombinant human interleukin-2 and human interferon-gamma. Thirty HLA-A*0201-matched patients with pr...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2009.101

    authors: Brill TH,Kübler HR,Pohla H,Buchner A,Fend F,Schuster T,van Randenborgh H,Paul R,Kummer T,Plank C,Eisele B,Breul J,Hartung R,Schendel DJ,Gansbacher B

    更新日期:2009-12-01 00:00:00

  • Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor.

    abstract::The therapeutic use of neurotrophic factors for neurodegenerative diseases is promising, however, optimal methods for continuous delivery of these substances to the human central nervous system (CNS) remains problematic. One approach would be to graft genetically engineered human cells that continuously secrete high l...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.3-331

    authors: Lin Q,Cunningham LA,Epstein LG,Pechan PA,Short MP,Fleet C,Bohn MC

    更新日期:1997-02-10 00:00:00

  • Adipose tissue as a novel target for in vivo gene transfer by adeno-associated viral vectors.

    abstract::Traditionally, skeletal muscle and liver are the preferred target organs for gene transfer to supply a transgene product into the systemic circulation. In this respect, adipose tissue presents a number of attractive features. However, adipose tissue transduction in vivo has not been feasible by conventional methods. T...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2006.17.921

    authors: Mizukami H,Mimuro J,Ogura T,Okada T,Urabe M,Kume A,Sakata Y,Ozawa K

    更新日期:2006-09-01 00:00:00

  • Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model.

    abstract::Neurodegeneration in Parkinson's disease (PD) affects mainly dopaminergic neurons in the substantia nigra, where age-related, increasing percentages of cells lose detectable respiratory activity associated with depletion of intact mitochondrial DNA (mtDNA). Replenishment of mtDNA might improve neuronal bioenergetic fu...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2009.023

    authors: Keeney PM,Quigley CK,Dunham LD,Papageorge CM,Iyer S,Thomas RR,Schwarz KM,Trimmer PA,Khan SM,Portell FR,Bergquist KE,Bennett JP Jr

    更新日期:2009-08-01 00:00:00

  • Protection of retroviral vector particles in human blood through complement inhibition.

    abstract::The rapid inactivation of murine-derived retroviral vectors in human or nonhuman primate sera is largely attributed to the activity of complement mediated through the classical pathway. In this study, we have further investigated the relationship between the human complement cascade and retrovirus inactivation. Preinc...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1995.6.4-429

    authors: Rother RP,Squinto SP,Mason JM,Rollins SA

    更新日期:1995-04-01 00:00:00

  • Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.

    abstract::Malignant pleural mesothelioma (MPM) is a fatal disease with a median survival of less than 14 months. For the first time, a genetically engineered vaccinia virus is shown to produce efficient infection, replication, and oncolytic effect against MPM. GLV-1h68 is a replication-competent engineered vaccinia virus carryi...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2008.036

    authors: Kelly KJ,Woo Y,Brader P,Yu Z,Riedl C,Lin SF,Chen N,Yu YA,Rusch VW,Szalay AA,Fong Y

    更新日期:2008-08-01 00:00:00

  • A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.

    abstract::This Phase I study, "Ribozyme Gene Therapy of HIV-1 Infection" (UCSD HSC #971072, FDA BB-IND 6405), is a prospective, open-label trial of infusion of autologous gene-altered cells into asymptomatic HIV-1 seropositive individuals. The objectives of this trial are to test the safety, feasibility, and potential efficacy ...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章

    doi:10.1089/hum.1998.9.16-2407

    authors: Wong-Staal F,Poeschla EM,Looney DJ

    更新日期:1998-11-01 00:00:00

  • Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells.

    abstract::Development of multidrug resistance (MDR) is the major obstacle to successful cancer chemotherapy. We have developed Daudi human lymphoma cells that are 20-fold more resistant than the parent cell line to vincristine (VCR) by infecting cells with pHaMDR1/A retroviral vector (Daudi/MDR20). Three DNA sequences of anti-M...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950018175

    authors: Wang FS,Kobayashi H,Liang KW,Holland JF,Ohnuma T

    更新日期:1999-05-01 00:00:00

  • Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice.

    abstract::Atrogin-1 or muscle atrophy F-box (MAFbx) is a major atrophy-related E3 ubiquitin ligase highly expressed in skeletal muscle during muscle atrophy and other disease states such as sepsis, cancer cachexia, and fasting. In this paper, we report experiments inhibiting MAFbx activity in fasting mice and in the skeletal my...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2010.057

    authors: Cong H,Sun L,Liu C,Tien P

    更新日期:2011-03-01 00:00:00

  • FUT-175, a synthetic inhibitor of the complement pathway, protects against the inactivation of infectious retroviruses by human serum.

    abstract::Serum-induced inactivation of retroviruses is the most critical limitation for in vivo gene transfer therapy. To solve this problem, we searched for reagents that protect retroviruses from inactivation. The effects of the protease inhibitors FOY-007 and FOY-305 and of an inhibitor of the complement pathway FUT-175, al...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.13-1575

    authors: Miyao Y,Ikenaka K,Kishima H,Tamura M,Nakamura K,Kurumi M,Hayakawa T,Shimizu K

    更新日期:1997-09-01 00:00:00

  • Differential Transgene Silencing of Myeloid-Specific Promoters in the AAVS1 Safe Harbor Locus of Induced Pluripotent Stem Cell-Derived Myeloid Cells.

    abstract::Targeted integration into a genomic safe harbor, such as the AAVS1 locus on chromosome 19, promises predictable transgene expression and reduces the risk of insertional mutagenesis in the host genome. The application of gamma-retroviral long terminal repeat (LTR)-driven vectors, which semirandomly integrate into the g...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.2019.194

    authors: Klatt D,Cheng E,Hoffmann D,Santilli G,Thrasher AJ,Brendel C,Schambach A

    更新日期:2020-02-01 00:00:00

  • Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo.

    abstract::Replication-deficient adenoviruses are known to induce acute injury and inflammation of infected tissues, thus limiting their use for human gene therapy. However, molecular mechanisms triggering this response have not been fully defined. To characterize this response, chemokine expression was evaluated in DBA/2 mice f...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950018364

    authors: Muruve DA,Barnes MJ,Stillman IE,Libermann TA

    更新日期:1999-04-10 00:00:00

  • Corrective transduction of human epidermal stem cells in laminin-5-dependent junctional epidermolysis bullosa.

    abstract::Laminin-5 is composed of three distinct polypeptides, alpha3, beta3, and gamma2, which are encoded by three different genes, LAMA3, LAMB3, and LAMC2, respectively. We have isolated epidermal keratinocytes from a patient presenting with a lethal form of junctional epidermolysis bullosa characterized by a homozygous mut...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.9-1359

    authors: Dellambra E,Vailly J,Pellegrini G,Bondanza S,Golisano O,Macchia C,Zambruno G,Meneguzzi G,De Luca M

    更新日期:1998-06-10 00:00:00

  • Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma.

    abstract::The purpose of this study was to determine the safety and antitumor activity of IFN-gamma retroviral vector in patients with advanced melanoma. Seventeen patients (9 single courses, 8 multiple courses) received a total of 363 intratumor injections of IFN-gamma retroviral vector (1 x 10(7) PFU/ml administered at 0.3, 0...

    journal_title:Human gene therapy

    pub_type: 临床试验,杂志文章

    doi:10.1089/10430349950017978

    authors: Nemunaitis J,Fong T,Burrows F,Bruce J,Peters G,Ognoskie N,Meyer W,Wynne D,Kerr R,Pippen J,Oldham F,Ando D

    更新日期:1999-05-20 00:00:00

  • A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells.

    abstract::The enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT) expressed by the parasite Trypanosoma brucei (Tb) can convert allopurinol, a purine analogue, to corresponding nucleotides with greater efficiency than its human homologue. We have developed a retroviral system that expresses the parasitic enzyme and te...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430340152528165

    authors: Trudeau C,Yuan S,Galipeau J,Benlimame N,Alaoui-Jamali MA,Batist G

    更新日期:2001-09-01 00:00:00

  • Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo.

    abstract::Recombinant adeno-associated virus (AAV) holds much promise for human gene therapy. While evidence indicates that AAV mediates long-term gene transfer in several different tissues, difficulty in preparing and purifying this viral vector in large quantities remains a major obstacle for evaluating AAV vectors in clinica...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303400750001390

    authors: Gao G,Qu G,Burnham MS,Huang J,Chirmule N,Joshi B,Yu QC,Marsh JA,Conceicao CM,Wilson JM

    更新日期:2000-10-10 00:00:00

  • A method of limited replication for the efficient in vivo delivery of adenovirus to cancer cells.

    abstract::Replication-deficient viral vectors are currently being used in gene transfer strategies to treat cancer cells. Unfortunately, viruses are limited in their ability to diffuse through tissue. This makes it virtually impossible to infect the majority of tumor cells in vivo and results in inadequate gene transfer. This p...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1998.9.8-1209

    authors: Han JS,Qian D,Wicha MS,Clarke MF

    更新日期:1998-05-20 00:00:00

  • Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy.

    abstract::The gene therapy strategy using the hsvl-thymidine kinase gene (TK) and ganciclovir (GCV) injections that has been used for treating human glioblastomas has not been as effective as expected after the first animal experiments. A better understanding of the different steps involved in this treatment, like gene transfer...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1997.8.16-1945

    authors: Sturtz FG,Waddell K,Shulok J,Chen X,Caruso M,Sanson M,Snodgrass HR,Platika D

    更新日期:1997-11-01 00:00:00

  • Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.

    abstract::DNA vaccination is an attractive approach for tumor immunotherapy because of its stability and simplicity of delivery. Advances demonstrate that helper T cell responses play a critical role in initiating immune responses. The aim of the current study is to test whether targeting HPV-16 E7 to the endosomal/lysosomal co...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/10430349950016474

    authors: Ji H,Wang TL,Chen CH,Pai SI,Hung CF,Lin KY,Kurman RJ,Pardoll DM,Wu TC

    更新日期:1999-11-20 00:00:00

  • In vivo trafficking and targeted delivery of magnetically labeled stem cells.

    abstract::Targeted delivery of intravenously administered genetically altered cells or stem cells is still in an early stage of investigation. We developed a method of delivering iron oxide (ferumoxide)-labeled mesenchymal stem cells (MSCs) to a targeted area in an animal model by applying an external magnet. Rats with or witho...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/104303404322959506

    authors: Arbab AS,Jordan EK,Wilson LB,Yocum GT,Lewis BK,Frank JA

    更新日期:2004-04-01 00:00:00

  • Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one.

    abstract::The T cell co-stimulatory molecule B7-1 was transduced into a poorly immunogenic murine neuroblastoma cell line (Neuro-2a, N-2a) alone or in combination with MHC class II genes to test the ability of these genes to stimulate antitumor immunity. N-2a cells transduced with B7-1 exhibited reduced tumorigenicity, whereas ...

    journal_title:Human gene therapy

    pub_type: 杂志文章

    doi:10.1089/hum.1996.7.17-2059

    authors: Heuer JG,Tucker-McClung C,Gonin R,Hock RA

    更新日期:1996-11-10 00:00:00